Gottlieb Places Drug Pricing Out Front In First Speech To US FDA Staff
Executive Summary
New FDA Commissioner tells employees that 'too many consumers are priced out of medicines they need' and that FDA must take meaningful steps to get lower cost alternatives to market.
You may also be interested in...
Generic Priority Review Expanded In Senate User Fee Bill
Amendment added during markup would require eight-month review of ANDAs for shortage drugs and those with limited competition, as well as pre-submission meetings.
Gottlieb Becomes US FDA Commissioner With Immediate Issues Pending
Senate confirmation includes fewest supporting votes for any candidate ever as agency tackles budget, user fees and other issues.
Gottlieb Closing In On Confirmation Despite Senate Concern On Opioids
US FDA commissioner nominee clears procedural hurdle as agency's opioid policy remains a charged political issue.